Global Drugs for Non-small Cell Lung Cancer Market Study 2016-2026, by Segment (Radiofrequency Ablation (RFA) , Radiation Therapy , … …), by Market (Hospital , Clinic , … …), by Company (Bristol-Myers Squibb , GlaxoSmithKline , … …)
SKU ID :99ST-14579484 | Published Date: 05-Oct-2019 | No. of pages: 85Description
Summary
The global Drugs for Non-small Cell Lung Cancer market will reach Volume Million USD in 2019 and with a CAGR xx% between 2020-2026.
Radiofrequency Ablation (RFA)
Radiation Therapy
Chemotherapy
Targeted Therapies
Immunotherapy
Demand Coverage (Market Size & Forecast, Consumer Distribution):
Hospital
Clinic
Others
Bristol-Myers Squibb
GlaxoSmithKline
Menarini
Sanofi
Ziopharm Oncology
Alchemia
Amgen
Apotex
BioMarin Pharmaceutical
CellAct Pharma
Cerulean Pharma
Cipla
Cornerstone Pharmaceuticals
Curis
CytRx
Eli Lilly
Exelixis
Fresenius Kabi
Genentech
Hikma Pharmaceuticals
Hospira
Intas Pharmaceuticals
Karyopharm Therapeutics
Kyowa Hakko Kirin
Ligand Pharmaceuticals
North America
Europe
Asia-Pacific
South America
Middle East & Africa
The global Drugs for Non-small Cell Lung Cancer market will reach Volume Million USD in 2019 and with a CAGR xx% between 2020-2026.
Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):
Radiofrequency Ablation (RFA)
Radiation Therapy
Chemotherapy
Targeted Therapies
Immunotherapy
Demand Coverage (Market Size & Forecast, Consumer Distribution):
Hospital
Clinic
Others
Company Coverage (Sales data, Main Products & Services etc.):
Bristol-Myers Squibb
GlaxoSmithKline
Menarini
Sanofi
Ziopharm Oncology
Alchemia
Amgen
Apotex
BioMarin Pharmaceutical
CellAct Pharma
Cerulean Pharma
Cipla
Cornerstone Pharmaceuticals
Curis
CytRx
Eli Lilly
Exelixis
Fresenius Kabi
Genentech
Hikma Pharmaceuticals
Hospira
Intas Pharmaceuticals
Karyopharm Therapeutics
Kyowa Hakko Kirin
Ligand Pharmaceuticals
Major Region
MarketNorth America
Europe
Asia-Pacific
South America
Middle East & Africa
TOC
Tables & Figures
Companies
- PRICE
-
$1800$3600Buy Now